[go: up one dir, main page]

SE0201937D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0201937D0
SE0201937D0 SE0201937A SE0201937A SE0201937D0 SE 0201937 D0 SE0201937 D0 SE 0201937D0 SE 0201937 A SE0201937 A SE 0201937A SE 0201937 A SE0201937 A SE 0201937A SE 0201937 D0 SE0201937 D0 SE 0201937D0
Authority
SE
Sweden
Prior art keywords
group
aryl
optionally substituted
alkyl group
fluoro
Prior art date
Application number
SE0201937A
Other languages
English (en)
Swedish (sv)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201937A priority Critical patent/SE0201937D0/xx
Publication of SE0201937D0 publication Critical patent/SE0201937D0/xx
Priority to PL03375078A priority patent/PL375078A1/xx
Priority to CA002490687A priority patent/CA2490687A1/en
Priority to PCT/GB2003/002598 priority patent/WO2004000295A1/en
Priority to US10/518,819 priority patent/US7521461B2/en
Priority to JP2004515010A priority patent/JP4327085B2/ja
Priority to KR10-2004-7020684A priority patent/KR20050014014A/ko
Priority to UA20041210011A priority patent/UA77527C2/uk
Priority to RU2004135542/04A priority patent/RU2339613C2/ru
Priority to BR0311840-1A priority patent/BR0311840A/pt
Priority to TW092116379A priority patent/TW200403209A/zh
Priority to EP03732715A priority patent/EP1517680A1/en
Priority to AU2003240101A priority patent/AU2003240101B2/en
Priority to MXPA04012694A priority patent/MXPA04012694A/es
Priority to NZ536972A priority patent/NZ536972A/en
Priority to CNB038143194A priority patent/CN100400512C/zh
Priority to ARP030102199A priority patent/AR040332A1/es
Priority to NO20045222A priority patent/NO20045222L/no
Priority to ZA200409690A priority patent/ZA200409690B/en
Priority to IL16567204A priority patent/IL165672A0/xx
Priority to IS7639A priority patent/IS7639A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SE0201937A 2002-06-20 2002-06-20 Therapeutic agents SE0201937D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
CNB038143194A CN100400512C (zh) 2002-06-20 2003-06-17 作为PPARα和γ调节剂的苯甲酸衍生物
RU2004135542/04A RU2339613C2 (ru) 2002-06-20 2003-06-17 ПРОИЗВОДНЫЕ БЕНЗОЙНОЙ КИСЛОТЫ КАК МОДУЛЯТОРЫ PPARα И PPARλ
TW092116379A TW200403209A (en) 2002-06-20 2003-06-17 Therapeutic agents
PCT/GB2003/002598 WO2004000295A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma
US10/518,819 US7521461B2 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of PPAR alpha and gamma
JP2004515010A JP4327085B2 (ja) 2002-06-20 2003-06-17 ＰＰＡＲαおよびγのモジュレーターとしての安息香酸誘導体
KR10-2004-7020684A KR20050014014A (ko) 2002-06-20 2003-06-17 Ｐｐａｒ 알파 및 감마의 조절물질로서 벤조산 유도체
UA20041210011A UA77527C2 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and ppar gamma, method of synthesis, pharmaceutical composition, intermediate
PL03375078A PL375078A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma
BR0311840-1A BR0311840A (pt) 2002-06-20 2003-06-17 Composto, formulação farmacêutica, método para tratar ou evitar resistência à insulina, uso de um composto, e, processo para prepará-lo
CA002490687A CA2490687A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma
EP03732715A EP1517680A1 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma
AU2003240101A AU2003240101B2 (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of PPAR alpha and gamma
MXPA04012694A MXPA04012694A (es) 2002-06-20 2003-06-17 DERIVADOS DE áCIDO BENZOICO COMO MODULARES DE RECEPTORES ACTIVADOS POR PROLIFERADOR DE PEROXIZOMA ( Y (.
NZ536972A NZ536972A (en) 2002-06-20 2003-06-17 Benzoic acid derivatives as modulators of ppar alpha and gamma
ARP030102199A AR040332A1 (es) 2002-06-20 2003-06-20 Derivados de acido benzoico como moduladores de ppar alfa y gamma
NO20045222A NO20045222L (no) 2002-06-20 2004-11-29 Benzosyrederivater som modulatorer av PPAR alfa og gamma
ZA200409690A ZA200409690B (en) 2002-06-20 2004-11-30 Benzoic acid derivatives as modulators PPAR alpha and gamma.
IL16567204A IL165672A0 (en) 2002-06-20 2004-12-09 Benzoic acid derivatives as modulators of prar alpha and gamma
IS7639A IS7639A (is) 2002-06-20 2005-01-12 Bensósýruafleiður sem stillar PPAR alfa og gamma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0201937D0 true SE0201937D0 (sv) 2002-06-20

Family

ID=20288295

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201937A SE0201937D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents

Country Status (21)

Country Link
US (1) US7521461B2 (es)
EP (1) EP1517680A1 (es)
JP (1) JP4327085B2 (es)
KR (1) KR20050014014A (es)
CN (1) CN100400512C (es)
AR (1) AR040332A1 (es)
AU (1) AU2003240101B2 (es)
BR (1) BR0311840A (es)
CA (1) CA2490687A1 (es)
IL (1) IL165672A0 (es)
IS (1) IS7639A (es)
MX (1) MXPA04012694A (es)
NO (1) NO20045222L (es)
NZ (1) NZ536972A (es)
PL (1) PL375078A1 (es)
RU (1) RU2339613C2 (es)
SE (1) SE0201937D0 (es)
TW (1) TW200403209A (es)
UA (1) UA77527C2 (es)
WO (1) WO2004000295A1 (es)
ZA (1) ZA200409690B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
JP3782818B2 (ja) * 2002-06-20 2006-06-07 アストラゼネカ アクチボラグ インスリン抵抗性の処置のためのオルト置換安息香酸誘導体
WO2005026134A1 (en) * 2003-09-17 2005-03-24 Novartis Ag Organic compounds
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CA2594345C (en) 2004-12-28 2013-11-05 Kinex Pharmaceuticals, Llc Compositions and methods of treating cell proliferation disorders
US7816405B2 (en) * 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
JP2007234800A (ja) 2006-02-28 2007-09-13 Tdk Corp 電子部品及びその製造方法
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
CA2656564C (en) * 2006-06-29 2015-06-16 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
RU2492858C2 (ru) 2007-04-11 2013-09-20 Омерос Корпорейшн Композиции и способы профилактики и лечения зависимостей
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8748423B2 (en) 2010-04-16 2014-06-10 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
CN105263907B (zh) 2012-08-30 2018-11-20 阿西纳斯公司 作为蛋白质酪氨酸激酶调节剂的n-(3-氟苄基)-2-(5-(4-吗啉代苯基)吡啶-2-基)乙酰胺
US11332457B2 (en) * 2017-11-30 2022-05-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition and use thereof
CN116601131A (zh) * 2020-10-23 2023-08-15 林伯士克洛索有限公司 Ctps1抑制剂及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) * 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
US5334753A (en) * 1992-03-12 1994-08-02 Rhone-Poulenc Agriculture Ltd Processes for preparing ortho-substituted benzoic acids
DE19615263A1 (de) * 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
DE19616948C1 (de) 1996-04-27 1997-11-27 Wagner Gmbh J Schneidwerkzeug, insbesondere Astschere
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
JP2001520193A (ja) * 1997-10-17 2001-10-30 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド キノリン誘導体の治療的使用
DK1040108T3 (da) 1997-12-19 2004-05-24 Schering Ag Orthoanthranilamidderivater som antikoagulanter
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
MXPA01010880A (es) 1999-04-28 2002-05-06 Aventis Pharma Gmbh Derivados de acido diarilico como ligandos de receptor ppar.
EE200100558A (et) 1999-04-28 2002-12-16 Aventis Pharma Deutschland Gmbh Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6509374B2 (en) * 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CA2490687A1 (en) 2003-12-31
RU2004135542A (ru) 2005-08-10
UA77527C2 (en) 2006-12-15
CN100400512C (zh) 2008-07-09
TW200403209A (en) 2004-03-01
WO2004000295A1 (en) 2003-12-31
US20050267149A1 (en) 2005-12-01
RU2339613C2 (ru) 2008-11-27
CN1662230A (zh) 2005-08-31
AU2003240101B2 (en) 2006-09-21
IS7639A (is) 2005-01-12
ZA200409690B (en) 2005-10-11
BR0311840A (pt) 2005-03-15
JP2006502105A (ja) 2006-01-19
IL165672A0 (en) 2006-01-15
JP4327085B2 (ja) 2009-09-09
NO20045222L (no) 2005-01-19
PL375078A1 (en) 2005-11-14
KR20050014014A (ko) 2005-02-05
MXPA04012694A (es) 2005-03-23
AU2003240101A1 (en) 2004-01-06
US7521461B2 (en) 2009-04-21
NZ536972A (en) 2006-06-30
EP1517680A1 (en) 2005-03-30
AR040332A1 (es) 2005-03-30

Similar Documents

Publication Publication Date Title
SE0201937D0 (sv) Therapeutic agents
ATE443990T1 (de) 3-heteroarylsubstituierte 5-methyloxymethyl- isoxazoline als herbizide
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
EA199700194A1 (ru) Производные пиразол-4-илбензоила и их применение в качестве гербицидов
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
CA2628131A1 (en) Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
RU2009143926A (ru) Производные пиридина, замещенные гетероциклическим циклом и фосфоноаминогруппой, и содержащее их противогрибковое средство
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
ATE259376T1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
ATE525366T1 (de) Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
ATE276257T1 (de) Pyrazinonderivate
UY28688A1 (es) Derivados de amida
RS51320B (sr) Derivati imidazohinolina kao veznici a3 receptora adenozina
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
AR035982A1 (es) Derivados de c-furano-2-il-metilamina y c-tiofeno-2-il-metilamina sustituidos y metodo de preparacion
ATE106877T1 (de) 4,5,6,7-tetrasubstituierte benzoxazolone.